enVVeno Medical/NVNO

$4.71

-1.46%
-
1D1W1MYTD1YMAX

About enVVeno Medical

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

Ticker

NVNO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Berman

Employees

31

Headquarters

Irvine, United States

enVVeno Medical Metrics

BasicAdvanced
$63.92M
Market cap
-
P/E ratio
-$1.96
EPS
1.13
Beta
-
Dividend rate
$63.92M
1.13074
$6.97
$2.51
130.4K
34.225
-52.09%
-55.38%
-53.82%
1.384
1.384
11%

What the Analysts think about enVVeno Medical

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
333.12% upside
High $20.40
Low $20.40
$4.71
Current price
$20.40
Average price target

enVVeno Medical Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-5.6M
12%
Profit margin
0%
-

enVVeno Medical Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.74%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.57
-$0.58
-$0.45
-$0.36
-
Expected
-$0.48
-$0.49
-$0.48
-$0.46
-$0.40
Surprise
18.75%
18.37%
-6.25%
-21.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for enVVeno Medical stock?

enVVeno Medical (NVNO) has a market cap of $63.92M as of April 20, 2024.

What is the P/E ratio for enVVeno Medical stock?

The price to earnings (P/E) ratio for enVVeno Medical (NVNO) stock is 0 as of April 20, 2024.

Does enVVeno Medical stock pay dividends?

No, enVVeno Medical (NVNO) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next enVVeno Medical dividend payment date?

enVVeno Medical (NVNO) stock does not pay dividends to its shareholders.

What is the beta indicator for enVVeno Medical?

enVVeno Medical (NVNO) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the enVVeno Medical stock price target?

The target price for enVVeno Medical (NVNO) stock is $20.4, which is 341.56% above the current price of $4.62. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell enVVeno Medical stock

Buy or sell enVVeno Medical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing